That I can't say. There is certainly lots of interest in Europe from clinicians in being part of a bisantrene clinical AML trial, but if they would pay for bisantrene I can't say. The history of the named patient program suggests it is difficult for clinicians to order bisantrene in Europe even if it is theoretically possible.
I do know that a number of European AML patients travelled to Israel to be treated in the Sheba 2 trial.
ASH2023 - Sheba 2.0, page-43
-
- There are more pages in this discussion • 114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
0.010(0.55%) |
Mkt cap ! $309.3M | |||
| Open | High | Low | Value | Volume |
| $1.81 | $1.85 | $1.75 | $154.4K | 85.93K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4739 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.83 | 7500 | 1 |
View Market Depth
| Last trade - 15.52pm 26/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |